AtonRa Partners Sells 502 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)

AtonRa Partners lowered its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 9.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,678 shares of the company’s stock after selling 502 shares during the period. AtonRa Partners’ holdings in Axsome Therapeutics were worth $372,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of AXSM. Raymond James Financial Services Advisors Inc. boosted its holdings in Axsome Therapeutics by 1.1% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 18,734 shares of the company’s stock valued at $1,309,000 after acquiring an additional 197 shares during the period. Fifth Third Bancorp grew its holdings in shares of Axsome Therapeutics by 100.0% in the third quarter. Fifth Third Bancorp now owns 400 shares of the company’s stock worth $28,000 after purchasing an additional 200 shares during the last quarter. Rafferty Asset Management LLC increased its stake in Axsome Therapeutics by 4.7% in the 3rd quarter. Rafferty Asset Management LLC now owns 4,560 shares of the company’s stock worth $319,000 after buying an additional 205 shares during the period. Amalgamated Bank lifted its holdings in Axsome Therapeutics by 5.2% during the 3rd quarter. Amalgamated Bank now owns 5,229 shares of the company’s stock valued at $365,000 after buying an additional 257 shares in the last quarter. Finally, Washington Trust Advisors Inc. purchased a new stake in Axsome Therapeutics in the 4th quarter valued at about $26,000. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Insider Buying and Selling

In other Axsome Therapeutics news, Director Roger Jeffs sold 29,976 shares of the stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $69.70, for a total value of $2,089,327.20. Following the completion of the sale, the director now directly owns 120,756 shares in the company, valued at $8,416,693.20. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other news, COO Mark L. Jacobson sold 24,662 shares of Axsome Therapeutics stock in a transaction on Monday, April 1st. The shares were sold at an average price of $77.24, for a total transaction of $1,904,892.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Roger Jeffs sold 29,976 shares of the business’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $69.70, for a total transaction of $2,089,327.20. Following the sale, the director now directly owns 120,756 shares in the company, valued at $8,416,693.20. The disclosure for this sale can be found here. 24.50% of the stock is owned by company insiders.

Axsome Therapeutics Stock Up 2.8 %

Shares of NASDAQ AXSM traded up $1.98 during trading hours on Monday, hitting $73.69. 505,671 shares of the stock were exchanged, compared to its average volume of 715,375. Axsome Therapeutics, Inc. has a 12 month low of $55.02 and a 12 month high of $98.40. The firm has a fifty day moving average price of $75.29 and a 200-day moving average price of $75.27. The company has a quick ratio of 3.52, a current ratio of 3.63 and a debt-to-equity ratio of 0.93. The company has a market cap of $3.49 billion, a PE ratio of -14.17 and a beta of 1.13.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings results on Tuesday, February 20th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.21) by $0.48. Axsome Therapeutics had a negative return on equity of 70.67% and a negative net margin of 88.41%. The business had revenue of $71.53 million for the quarter, compared to the consensus estimate of $70.38 million. On average, sell-side analysts expect that Axsome Therapeutics, Inc. will post -3.81 EPS for the current year.

Wall Street Analyst Weigh In

AXSM has been the topic of a number of research reports. Truist Financial reaffirmed a “buy” rating and set a $150.00 target price on shares of Axsome Therapeutics in a research report on Tuesday, March 26th. Morgan Stanley upgraded Axsome Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $90.00 to $115.00 in a report on Monday. Cantor Fitzgerald reiterated an “overweight” rating and issued a $107.00 target price on shares of Axsome Therapeutics in a report on Wednesday, April 10th. HC Wainwright restated a “buy” rating and set a $190.00 price target on shares of Axsome Therapeutics in a research note on Tuesday, April 2nd. Finally, Robert W. Baird assumed coverage on shares of Axsome Therapeutics in a research note on Tuesday, March 19th. They issued an “outperform” rating and a $108.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $122.00.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.